LCL-161 (NVP-LCL161): A Comprehensive Monograph on a Monovalent SMAC Mimetic IAP Antagonist

Executive Summary

LCL-161 is an orally bioavailable, investigational small molecule developed as a Second Mitochondria-derived Activator of Caspases (SMAC) mimetic.[1] Its primary therapeutic objective is to counteract a key cancer survival mechanism by antagonizing the Inhibitor of Apoptosis Protein (IAP) family, thereby restoring the intrinsic apoptotic potential of malignant cells.[2] As a monovalent, pan-IAP inhibitor, LCL-161 potently targets cellular IAP1 (cIAP1), cIAP2, and X-linked IAP (XIAP). Its mechanism of action involves inducing the rapid proteasomal degradation of cIAPs, which in turn unleashes the non-canonical NF-κB signaling pathway and promotes TNFα-dependent apoptosis.[4]

Preclinical evaluation of LCL-161 established a strong scientific rationale for its use in combination therapies. While demonstrating limited single-agent activity across most cancer models, it proved to be a potent chemosensitizer and radiosensitizer, synergizing with a range of cytotoxic agents, targeted therapies, and radiation.[8] This promising preclinical profile, however, did not consistently translate into broad clinical success. As a monotherapy in early-phase trials for advanced solid tumors, LCL-161 failed to produce objective responses.[11] The most significant clinical efficacy was observed in a Phase 2 trial for myelofibrosis, a disease characterized by a unique, TNFα-rich inflammatory microenvironment that appears to "prime" cancer cells for LCL-161's mechanism of action. In this setting, LCL-161 monotherapy achieved a meaningful objective response rate and provided clinical benefit, particularly in improving anemia.[13]

The clinical development of LCL-161 was ultimately constrained by its safety profile and a narrow therapeutic window. The on-target pharmacodynamic effect of IAP inhibition leads directly to the dose-limiting toxicity of Cytokine Release Syndrome (CRS), an inflammatory state driven by the release of TNFα and other cytokines.[11] Furthermore, attempts to combine LCL-161 with cytotoxic chemotherapy were complicated by synergistic toxicities, such as severe myelosuppression observed with topotecan.[16] Consequently, the originator, Novartis, has discontinued the broader development of LCL-161, with several key clinical trials being terminated due to a stated "change in development strategy".[17] The journey of LCL-161 provides critical insights into the therapeutic potential and inherent challenges of the SMAC mimetic drug class, underscoring the importance of patient stratification based on tumor microenvironment and the careful selection of combination partners with non-overlapping toxicity profiles.

Compound Profile and Physicochemical Characteristics

A precise and unambiguous identification of an investigational compound is foundational to its scientific and clinical evaluation. This section provides a comprehensive summary of the nomenclature, registry identifiers, and key chemical and physical properties of LCL-161.

Nomenclature and Identifiers

LCL-161 has been referenced by several names and unique identifiers across chemical databases, clinical trial registries, and scientific literature.

• Primary Name: LCL-161 [19]
• Synonyms: LCL161, LCL 161, NVP-LCL161, SMAC mimetic LCL161 [1]
• Registry Numbers:
• CAS Number: 1005342-46-0 (free base).[1] Related forms include 2095244-42-9 (phenol) and 1263876-34-1 (hemihydrate).[1]
• DrugBank ID: DB12085 [19]
• PubChem CID: 24737642 [20]
• FDA UNII (Unique Ingredient Identifier): 6TNS415Y3P [19]
• NCI Thesaurus Code: C91079 [3]
• European Community (EC) Number: 811-361-6 [20]
• ChEMBL ID: CHEMBL2431768 [20]

Chemical Structure and Properties

LCL-161 is a synthetically derived small molecule with characteristics that support its development as an oral therapeutic agent.

• Drug Type/Modality: Small Molecule [28]
• Chemical Class: LCL-161 is classified as a dipeptide, consisting of a sequence of two alpha-amino acids linked by a peptide bond.[28] It is also categorized as a synthetic organic compound.[22]
• IUPAC Name: (S)-N-((S)-1-cyclohexyl-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide [1]
• Molecular Formula: $C_{26}H_{33}FN_{4}O_{3}S$ [1]
• Molecular Weight:
• Average: 500.63 g/mol [1]
• Monoisotopic: 500.225740276 g/mol [28]
• Structural Codes:
• SMILES: C[C@H](NC)C(N[C@@H](C1CCCCC1)C(N2[C@H](C3=NC(C(C4=CC=C(F)C=C4)=O)=CS3)CCC2)=O)=O [1]
• InChIKey: UFPFGVNKHCLJJO-SSKFGXFMSA-N [1]
• Solubility and Formulation: LCL-161 exhibits solubility in common laboratory organic solvents, including DMF (30 mg/ml), DMSO (20 mg/ml), and Ethanol (20 mg/ml).[21] For preclinical in vivo studies requiring oral administration, it has been formulated as a homogeneous suspension in carboxymethylcellulose sodium (CMC-Na) or as a solution by dissolving in 0.1N HCl followed by dilution with a sodium acetate buffer.[4] This versatility in formulation is essential for conducting robust preclinical evaluations.

The physicochemical properties of LCL-161 align well with the criteria for orally bioavailable drugs, as assessed by Lipinski's Rule-of-Five. With a molecular weight just over 500 g/mol, 2 hydrogen bond donors, 7 hydrogen bond acceptors, and a calculated lipophilicity (XLogP) of 3.95, the molecule breaks no Lipinski's rules, predicting favorable absorption and permeation characteristics essential for an oral drug.[22]

Table 1: Compound Identifiers and Physicochemical Properties of LCL-161

Parameter	Value	Source(s)
Primary Name	LCL-161	19
CAS Number	1005342-46-0	[1, 20, 25]
DrugBank ID	DB12085	19
PubChem CID	24737642	20
Chemical Class	Dipeptide, Small Molecule	28
Molecular Formula	$C_{26}H_{33}FN_{4}O_{3}S$	[20, 28]
Average Molecular Weight	500.63 g/mol	[20, 28]
IUPAC Name	(S)-N-((S)-1-cyclohexyl-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide	1
SMILES	C[C@H](NC)C(N[C@@H](C1CCCCC1)C(N2[C@H](C3=NC(C(C4=CC=C(F)C=C4)=O)=CS3)CCC2)=O)=O	[1, 20]
InChIKey	UFPFGVNKHCLJJO-SSKFGXFMSA-N	1
Hydrogen Bond Acceptors	7	22
Hydrogen Bond Donors	2	22
Topological Polar Surface Area	119.64 $Å^{2}$	22
XLogP	3.95	22
Lipinski's Rules Broken	0	22

Pharmacological Profile: Mechanism of Action and Biological Effects

LCL-161 is a targeted therapeutic agent designed to exploit a fundamental vulnerability in cancer cells: their dependence on the suppression of apoptosis. Its mechanism of action is multifaceted, involving direct protein antagonism, modulation of key signaling pathways, and reprogramming of the tumor microenvironment.

Primary Mechanism: Antagonism of Inhibitor of Apoptosis Proteins (IAPs)

The central mechanism of LCL-161 is its function as a SMAC mimetic. In healthy cells under apoptotic stress, the endogenous protein SMAC/DIABLO is released from the mitochondria into the cytosol, where it binds to and neutralizes IAP proteins, thereby permitting the execution of programmed cell death.[7] Many cancer cells subvert this process by overexpressing IAPs to shield themselves from apoptosis.[2] LCL-161 is engineered to mimic the N-terminal IAP-binding motif of SMAC, restoring this pro-apoptotic signal.[2]

LCL-161 is characterized as a monovalent, pan-IAP inhibitor, meaning it has a single binding moiety and interacts with high affinity across multiple members of the IAP family.[6] Its primary targets include:

• Cellular IAP1 (cIAP1/BIRC2) and Cellular IAP2 (cIAP2/BIRC3): These IAPs are key regulators of the NF-κB signaling pathway and cell survival.
• X-linked IAP (XIAP/BIRC4): This is the only IAP family member that directly inhibits the enzymatic activity of both initiator (caspase-9) and executioner (caspase-3, -7) caspases.[6]
• Other targets include BIRC5 (Survivin) and NAIP (BIRC1).[3]

The potency of LCL-161 against its key targets has been quantified in cell-based assays, revealing a particularly high affinity for cIAP1:

• cIAP1: $IC_{50} = 0.4$ nM (in MDA-MB-231 cells) [5]
• XIAP: $IC_{50} = 35$ nM (in HEK293 cells) [5]

Downstream Signaling and Cellular Consequences

The binding of LCL-161 to IAPs triggers a cascade of downstream events that converge to induce cancer cell death.

1. Induction of cIAP Degradation: The primary and most immediate consequence of LCL-161 binding to cIAP1 and cIAP2 is the induction of their E3 ubiquitin ligase activity, leading to rapid auto-ubiquitylation and subsequent degradation by the proteasome.[4] This degradation is a key pharmacodynamic biomarker of drug activity and has been confirmed in preclinical models and in patient-derived tissues.[11]
2. Activation of the Non-Canonical NF-κB Pathway: cIAP1 and cIAP2 are critical negative regulators of the non-canonical NF-κB pathway. By targeting NF-κB-inducing kinase (NIK) for degradation, they keep this pathway dormant. The degradation of cIAPs by LCL-161 leads to the stabilization and accumulation of NIK.[7] NIK then phosphorylates and activates IKKα, which in turn processes the NF-κB2 precursor protein p100 into the active p52 subunit, a hallmark of non-canonical pathway activation.[31]
3. TNFα-Dependent Cell Death: A major transcriptional target of the activated NF-κB pathway is the pro-inflammatory cytokine TNFα.[7] The subsequent secretion of TNFα creates an autocrine or paracrine feedback loop, where TNFα binds to its receptor, TNFR1, on the surface of cancer cells. In a normal cell, cIAPs are recruited to the TNFR1 signaling complex to promote pro-survival signaling. However, in the presence of LCL-161, cIAPs are depleted. This shifts the balance of the TNFR1 complex from survival to death, leading to the recruitment of FADD and pro-caspase-8 to form a death-inducing signaling complex (DISC). This complex activates caspase-8, which then triggers a downstream caspase cascade (activating caspase-3 and -7), culminating in apoptosis.[15] In certain cellular contexts, particularly where caspase activity is blocked, this same pathway can be shunted towards programmed necrosis (necroptosis) through the RIP1/RIP3/MLKL signaling axis.[6]

This mechanistic linkage between IAP degradation, NF-κB activation, and TNFα-mediated cell death is fundamental to LCL-161's activity. It also explains why its efficacy is highly context-dependent and why it is the direct source of its primary dose-limiting toxicity, Cytokine Release Syndrome (CRS), which is driven by systemic elevation of TNFα and other inflammatory cytokines.[11] The therapeutic effect and the main toxicity are two sides of the same mechanistic coin, creating an inherently narrow therapeutic window.

Immunomodulatory Functions

Beyond its direct effects on tumor cells, LCL-161 exerts significant influence on the immune system and the tumor microenvironment.

• T-Cell Modulation: LCL-161 has been shown to provide a costimulatory signal to T cells, enhancing antigen-driven proliferation, survival, and cytokine secretion.[4] This suggests potential for synergy with immunotherapies. However, this effect is complicated by the finding that LCL-161 can also sensitize T cells to Fas-mediated apoptosis.[31] This dual effect—simultaneously boosting T-cell function while making them more susceptible to death—creates a complex biological paradox that may limit its utility in combination with T-cell-based therapies.
• Macrophage Reprogramming: In preclinical models, LCL-161, especially when combined with T-cell-derived cytokines like IFNγ, can reprogram macrophages to phagocytose live cancer cells. This implicates macrophages as a critical cellular target for the drug's anti-cancer activity and suggests a mechanism that is independent of IAP status within the tumor cell itself.[34]
• Dendritic Cell Maturation: LCL-161 can induce the phenotypic maturation of myeloid dendritic cells, although this may be accompanied by a reduced capacity to cross-present tumor antigens.[4]

Comparative Analysis within the SMAC Mimetic Class

The therapeutic profile of LCL-161 is best understood in the context of other SMAC mimetics in development. Key differentiators include molecular structure (valency) and target selectivity.

• Valency: LCL-161 is a monovalent agent, possessing one SMAC-mimetic binding motif.[6] This contrasts with agents like birinapant, which is a bivalent mimetic containing two binding motifs joined by a chemical linker. Bivalency is designed to confer higher potency and affinity by engaging two binding sites on IAP proteins simultaneously.[6]
• Target Selectivity: LCL-161 and GDC-0152 are considered pan-IAP inhibitors, binding with roughly similar affinities to cIAP1, cIAP2, and XIAP.[6] In contrast, birinapant preferentially targets cIAP1 and cIAP2 over XIAP.[6] This distinction in target profile can lead to different biological outcomes and toxicity profiles. For instance, the improved tolerability of second-generation bivalent mimetics like birinapant has been associated with reduced affinity for XIAP.[35]

Preclinical Evaluation: In Vitro and In Vivo Antineoplastic Activity

The preclinical assessment of LCL-161 revealed a compound with modest single-agent breadth but significant potential as a synergistic partner for conventional and targeted cancer therapies. This body of evidence provided the foundational rationale for its advancement into clinical trials.

Single-Agent Potency and Activity

In vitro screening of LCL-161 against large panels of cancer cell lines demonstrated highly variable single-agent cytotoxic activity, a critical finding that guided its clinical development strategy.

• Highly Sensitive Histologies: The most pronounced single-agent activity was observed in select hematologic malignancies. Potent growth inhibition was noted in T-cell acute lymphoblastic leukemia (T-cell ALL) cell lines, such as CCRF-CEM ($IC_{50} = 0.25$ μM) and COG-LL-317, and in the anaplastic large cell lymphoma (ALCL) cell line Karpas-299 ($IC_{50} = 1.6$ μM).[4] Additionally, it showed efficacy against Ba/F3 cells engineered to express specific oncogenic drivers, including BCR-ABL (p210) ($IC_{50} \approx 100$ nM) and the FLT3-D835Y mutation ($IC_{50} \approx 50$ nM).[4]
• Moderately Sensitive Histologies: In solid tumors, single-agent activity was generally more modest. In human hepatocellular carcinoma (HCC), LCL-161 inhibited cell proliferation in Hep3B ($IC_{50} = 10.23$ μM) and PLC5 ($IC_{50} = 19.19$ μM) cell lines, an effect that was found to be dependent on the expression of Bcl-2.[5] In breast cancer, it demonstrated potent antiproliferative activity against the MDA-MB-231 cell line ($IC_{50} = 7.8$ nM).[5]
• Resistant Histologies: A key finding from the Pediatric Preclinical Testing Program (PPTP) was that LCL-161 exhibited limited single-agent breadth. It achieved 50% growth inhibition against only 3 of the 23 cell lines tested at concentrations up to 10 μM, with a median relative $IC_{50}$ value greater than 10 μM.[1] This widespread resistance as a single agent strongly suggested that its clinical utility would likely depend on combination strategies.

Table 2: In Vitro Potency of LCL-161 Across Key Targets and Cancer Cell Lines

Target / Cell Line	Assay Type	Potency Value (IC50​/EC50​)	Source(s)
cIAP1 (in MDA-MB-231)	IAP Inhibition	0.4 nM	5
XIAP (in HEK293)	IAP Inhibition	35 nM	5
MDA-MB-231 (Breast Cancer)	Antiproliferative	7.8 nM	5
SK-OV-3 (Ovarian Cancer)	Apoptosis Induction	1 nM	5
Ba/F3-D835Y (Leukemia Model)	Antiproliferative	~50 nM	4
Ba/F3.p210 (Leukemia Model)	Antiproliferative	~100 nM	4
CCRF-CEM (T-cell ALL)	Antiproliferative	0.25 μM	4
Karpas-299 (ALCL)	Antiproliferative	1.6 μM	4
Hep3B (Hepatocellular Carcinoma)	Antiproliferative	10.23 μM	[5, 25]
PLC5 (Hepatocellular Carcinoma)	Antiproliferative	19.19 μM	[5, 25]

Synergistic Potential in Combination Regimens

The most compelling aspect of LCL-161's preclinical profile is its ability to act as a potent sensitizer to other anticancer therapies by lowering the apoptotic threshold of tumor cells.

• Combination with Chemotherapy: LCL-161 demonstrated strong synergy with multiple classes of cytotoxic agents. In non-small cell lung cancer (NSCLC) models, it cooperated with paclitaxel to reduce cell viability and induce apoptosis.[32] In neuroblastoma, a strong synergistic inhibition of proliferation was observed with vinca alkaloids (vinblastine, vincristine, vindesine).[10] In preclinical models of rituximab-resistant B-cell lymphoma, LCL-161 synergistically enhanced the antitumor effect of gemcitabine.[8] It also showed synergy with doxorubicin in osteosarcoma models.[29]
• Combination with Targeted Therapy: In leukemia models driven by FLT3 mutations, LCL-161 combined synergistically with the FLT3 kinase inhibitor PKC412. This combination was powerful enough to overcome the protective effects conferred by bone marrow stromal cells, a common mechanism of drug resistance.[4]
• Combination with Radiotherapy: LCL-161 was identified as an effective radiosensitizer. This effect was particularly pronounced in human papillomavirus-negative (HPV[-]) head and neck squamous cell carcinoma (HNSCC) cells. These tumors were found to have higher baseline expression of cIAP1, making them theoretically more dependent on this anti-apoptotic protein and thus more vulnerable to its degradation by LCL-161 prior to radiation.[9]

Activity in Animal Models

In vivo studies using xenograft models largely confirmed the observations from cell culture: LCL-161 has limited efficacy on its own but becomes a potent anticancer agent when combined with other treatments.

• Single-Agent Activity: As a single agent, LCL-161 demonstrated limited activity against the PPTP in vivo panels. While it did not produce objective tumor responses, it induced statistically significant differences in event-free survival (EFS) distribution in approximately one-third of solid tumor xenografts, including osteosarcoma and glioblastoma models.[1]
• Combination Activity: The true potential of LCL-161 was revealed in combination studies. In a severe combined immunodeficient (SCID) mouse model of rituximab-resistant B-cell lymphoma, the addition of LCL-161 to the chemotherapy regimen of rituximab, gemcitabine, and vinorelbine (RGV) significantly improved in vivo survival compared to RGV alone.[8] Similarly, in HPV[-] HNSCC tumor xenografts, the combination of LCL-161 and radiotherapy led to dramatic tumor regression, which was accompanied by pharmacodynamic evidence of on-target cIAP1 degradation and apoptosis activation.[9]

Clinical Development Program and Efficacy Analysis

The clinical development of LCL-161 spanned multiple Phase 1 and Phase 2 trials, evaluating the drug as both a monotherapy and in combination regimens across a range of solid and hematologic malignancies. The program's trajectory reveals a compound with a clear, albeit narrow, path of clinical activity, ultimately leading to its discontinuation by the developer.

Phase 1 First-in-Human Studies in Advanced Solid Tumors

The initial clinical evaluation of LCL-161 was conducted in a first-in-human, dose-escalation study (NCT01098838) in patients with advanced solid tumors.[39] The primary objectives were to assess safety, determine the maximum tolerated dose (MTD), and characterize the pharmacokinetic and pharmacodynamic profiles.[11]

• Study Design: Patients received oral LCL-161 once weekly on a 21-day cycle, with doses ranging from 10 mg to 3,000 mg.[11]
• Key Outcomes:
• Safety and Dose: The drug was generally well-tolerated at doses up to 1,800 mg. The sole dose-limiting toxicity (DLT) was Cytokine Release Syndrome (CRS), an on-target inflammatory response. Although an MTD was not formally declared, the 1,800 mg weekly dose was selected as the Recommended Phase 2 Dose (RP2D) for further investigation.[11]
• Pharmacodynamics: The study successfully demonstrated target engagement in humans. Administration of LCL-161 led to the degradation of cIAP1 protein in peripheral blood mononuclear cells, skin biopsies, and tumor tissue, and was associated with a dose-dependent increase in circulating inflammatory cytokines.[11]
• Efficacy: In line with preclinical predictions for broad, unselected tumor types, no objective responses were observed in this study.[11] This pivotal finding established that LCL-161 lacks meaningful single-agent activity in advanced solid tumors and that its future would depend on identifying specific, sensitive patient populations or effective combination strategies.

Phase 2 Investigations in Hematologic Malignancies

Following the Phase 1 results, the clinical strategy shifted towards indications where a stronger biological rationale for single-agent activity existed.

• Myelofibrosis (NCT02098161): This single-center, investigator-initiated Phase 2 trial represents the clinical high point for LCL-161.[13] The study was predicated on the hypothesis that the inherently pro-inflammatory, TNFα-rich microenvironment of myelofibrosis (MF) would "prime" malignant cells for the pro-apoptotic effects of IAP inhibition.[13]
• Design: Patients with treatment-resistant MF received LCL-161 monotherapy, starting at a dose of 1500 mg weekly.[13]
• Efficacy: The trial met its primary objective, demonstrating an objective response rate (ORR) of 30-32% by IWG-MRT criteria.[13] A particularly noteworthy finding was the clinical improvement in anemia in 6 responding patients, including two who became transfusion-independent, addressing a major unmet need in MF.[13] The median overall survival (OS) was 34 months, a promising result in this high-risk, heavily pre-treated population.[13] These results validated the "primed microenvironment" hypothesis and showed that in the right biological context, LCL-161 could elicit meaningful clinical benefit.
• Multiple Myeloma: LCL-161 was evaluated in multiple myeloma (MM) in at least two key trials.
• NCT01955434: A completed Phase 2 study evaluated LCL-161 as a single agent or in combination with cyclophosphamide for patients with relapsed or refractory MM.[42] While some durable anti-tumor responses were reported, the overall results were not sufficient to drive further development in this indication.[13]
• NCT03111992: A completed Phase 1 trial explored the combination of LCL-161 with the anti-PD-1 antibody spartalizumab (PDR001) in patients with MM.[45]

Investigations in Solid Tumors

Efforts in solid tumors focused primarily on combination strategies, leveraging the strong preclinical synergy data.

• Triple-Negative Breast Cancer (TNBC) (NCT01617668): A randomized Phase 2 study evaluated the addition of LCL-161 to standard neoadjuvant chemotherapy with weekly paclitaxel. This trial has been completed, but its results did not lead to a Phase 3 investigation.[4]
• Other Combination Trials: Several Phase 1 studies explored various combinations, including with paclitaxel in advanced solid tumors (NCT01240655) and with the mTOR inhibitor everolimus or the HDAC inhibitor panobinostat (NCT02890069).[48] These trials have also completed, but the lack of progression to later-stage studies suggests that these combinations either failed to meet efficacy benchmarks or presented unacceptable toxicity.

Terminated and Discontinued Trials

The ultimate fate of the LCL-161 program is defined by the termination of several key studies, signaling a strategic retreat from its development.

• LCL-161 plus Topotecan (NCT02649673): This Phase 1/2 trial in small-cell lung cancer (SCLC) and gynecologic malignancies was terminated early.[16] The rationale for termination was clear: the combination led to excessive and intolerable myelosuppression, with grade 3/4 thrombocytopenia and anemia rates exceeding 50% and 30%, respectively, without a corresponding improvement in clinical outcomes.[16] This outcome exemplifies the "combination toxicity trap"—where preclinical synergy is overshadowed by synergistic toxicity in the clinic.
• Japanese Phase 1 Study (NCT01968915): This study in Japanese patients with advanced solid tumors was terminated by Novartis explicitly due to a "change in development strategy of LCL161".[17] This action, along with the discontinuation of other trials, effectively marked the end of the broad clinical development of LCL-161.

Table 3: Summary of Major Clinical Trials for LCL-161

NCT Identifier	Phase	Indication(s)	Intervention(s)	Status	Sponsor / Collaborators	Key Findings / Rationale
NCT01098838	1	Advanced Solid Tumors	LCL-161 Monotherapy	Completed	Novartis	Established RP2D of 1800 mg weekly. DLT was CRS. No objective responses observed. 11
NCT02098161	2	Myelofibrosis	LCL-161 Monotherapy	Completed	M.D. Anderson Cancer Center	Positive trial. ORR of 30-32%. Notable improvement in anemia. Median OS of 34 months. 13
NCT01955434	2	Multiple Myeloma	LCL-161 +/- Cyclophosphamide	Completed	Mayo Clinic	Evaluated LCL-161 in relapsed/refractory MM. Durable responses reported but did not lead to pivotal trials. [42, 43, 47]
NCT01617668	2	Triple-Negative Breast Cancer	Paclitaxel +/- LCL-161	Completed	Novartis	Neoadjuvant study. Did not progress to Phase 3. 4
NCT01240655	1	Advanced Solid Tumors	Paclitaxel + LCL-161	Completed	Novartis	Early-phase combination study. [47, 49]
NCT02649673	1/2	SCLC, Ovarian Cancer	Topotecan + LCL-161	Terminated	SCRI Development Innovations	Terminated due to excessive myelosuppression and lack of improved efficacy. [16, 18]
NCT01968915	1	Advanced Solid Tumors (Japan)	LCL-161 Monotherapy	Terminated	Novartis	Terminated due to "change in development strategy," signaling halt of program. [17, 47]

Human Pharmacokinetics and Safety Profile

A comprehensive understanding of a drug's absorption, distribution, metabolism, and excretion (ADME) profile, along with its clinical safety and tolerability, is essential for evaluating its therapeutic potential and defining its place in therapy.

Clinical Pharmacokinetics (ADME Profile)

Data from Phase 1 clinical studies provided key insights into the pharmacokinetic behavior of LCL-161 in humans.

• Absorption: LCL-161 is an orally bioavailable agent that is rapidly absorbed following administration.[1] In the first-in-human trial, plasma exposure, as measured by area under the curve (AUC), was observed to generally increase with the administered dose.[11] The study also compared a liquid solution formulation to a solid tablet formulation. While both formulations provided similar systemic exposures, the tablet was significantly better tolerated by patients, leading to the discontinuation of the liquid solution for further development.[11]
• Distribution: While specific human pharmacokinetic parameters such as volume of distribution are not detailed in the available materials, pharmacodynamic data from the Phase 1 study confirmed that LCL-161 distributes to relevant tissues. Evidence of on-target cIAP1 degradation was observed not only in circulating blood cells but also in skin and tumor biopsies, indicating that the drug reaches and is active in both peripheral and target tissues.[11]
• Metabolism: In vitro studies using human liver microsomes and hepatocytes have identified a significant potential for drug-drug interactions. LCL-161 was found to be a concentration- and time-dependent inhibitor of the major drug-metabolizing enzyme Cytochrome P450 3A4/5 (CYP3A), with an inhibition constant ($K_I$) of 0.797 μM.[5] Additionally, LCL-161 was shown to activate the pregnane X receptor (PXR), a nuclear receptor that regulates the expression of drug-metabolizing enzymes, and induced CYP3A4 mRNA expression in human hepatocytes.[5] This dual role as both an inhibitor and an inducer of the CYP3A4 pathway complicates its use in combination therapies, as it could alter the metabolism and exposure of co-administered drugs that are CYP3A4 substrates.
• Excretion: Detailed information regarding the primary routes of elimination (e.g., renal vs. hepatic clearance) and the terminal half-life of LCL-161 in humans is not available in the provided documentation.

Clinical Safety and Tolerability

The safety profile of LCL-161 has been characterized across multiple clinical trials, revealing a consistent pattern of on-target inflammatory toxicities and, in combination settings, the potential for synergistic adverse effects.

• Dose-Limiting Toxicity: The most significant and defining toxicity of LCL-161 monotherapy is Cytokine Release Syndrome (CRS). In the pivotal Phase 1 study (NCT01098838), CRS was the sole DLT, observed in 3 of 53 patients (6%), and was the most common grade 3-4 adverse event, occurring in 5 of 53 patients (9%).[11] This is a direct consequence of the drug's mechanism of action, which involves the upregulation of inflammatory cytokines like TNFα.
• Common Adverse Events (Grade 1-2): The most frequently reported side effects were generally low-grade and manageable. Data from the Phase 2 myelofibrosis trial (NCT02098161) provides a clear picture of the common toxicity profile:
• Gastrointestinal: Nausea/vomiting (64%), Diarrhea (26%)
• Constitutional: Fatigue (46%), Fever/flu-like syndrome (34%), Dizziness/vertigo (30%)
• Dermatologic: Pruritus (26%), Skin eruption/rash (24%)
• Other: Pain (26%) [15]
• Serious Adverse Events (Grade 3-4):
• Monotherapy (Myelofibrosis Trial): In the context of monotherapy for a heavily pre-treated population, LCL-161 was relatively well-tolerated. Grade 3/4 events were infrequent and included syncope (4%), nausea/vomiting (2%), and skin eruption/pruritus (2%). Hematologic toxicities included thrombocytopenia (6%) and anemia (4%).[15]
• Combination Therapy (Topotecan Trial): The safety profile changed dramatically in combination with myelosuppressive chemotherapy. In the terminated trial with topotecan (NCT02649673), the most frequent grade 3/4 treatment-related adverse events were hematologic: thrombocytopenia (51.43%) and anemia (31.43%).[16] This severe, overlapping toxicity highlighted the significant challenge of combining LCL-161 with conventional cytotoxic agents.

Table 4: Treatment-Related Adverse Events (AEs) in Patients with Myelofibrosis Treated with LCL-161 (NCT02098161)

Adverse Event	Grade	Number of Patients (n)	Percentage (%)
Nonhematologic AEs
Nausea/vomiting	1/2	32	64
Fatigue	1/2	23	46
Fever/flu-like syndrome	1/2	17	34
Dizziness/vertigo	1/2	15	30
Pruritus	1/2	13	26
Diarrhea	1/2	13	26
Pain	1/2	13	26
Skin eruption/rash	1/2	12	24
Syncope	3/4	2	4
Nausea/vomiting	3/4	1	2
Skin eruption/pruritus	3/4	1	2
Hematologic AEs
Thrombocytopenia	3/4	3	6
Anemia	3/4	2	4
Data adapted from the final results of the Phase 2 clinical trial in myelofibrosis.[15]

Concluding Analysis and Future Perspective

The clinical development journey of LCL-161 offers a compelling case study in the translation of a novel biological mechanism from the laboratory to the clinic. The comprehensive data from preclinical studies to Phase 2 trials provides a clear, albeit complex, picture of the drug's potential and its ultimate limitations.

Integrated Efficacy and Safety Assessment

LCL-161's therapeutic potential is fundamentally governed by a narrow therapeutic window, a direct consequence of its on-target pharmacology. The molecular mechanism that drives its intended anticancer effect—the degradation of cIAPs leading to NF-κB activation and TNFα-mediated apoptosis—is the very same mechanism that causes its primary dose-limiting toxicity, Cytokine Release Syndrome.[7] This intrinsic linkage means that enhancing efficacy by increasing dose is inherently tied to an increased risk of severe inflammatory toxicity.

As a monotherapy, LCL-161 demonstrated a lack of meaningful activity in unselected advanced solid tumors.[11] Its only significant single-agent success came in myelofibrosis, a disease uniquely characterized by a pre-existing TNFα-rich microenvironment that effectively "primes" the tumor for LCL-161's action.[13] This success was not an anomaly but rather a confirmation of the drug's TNFα-dependent mechanism, highlighting that its efficacy is highly context-dependent. While preclinical studies showcased LCL-161 as a powerful synergistic agent, this potential was difficult to realize clinically. The attempt to combine it with topotecan was terminated due to an unacceptable level of overlapping myelosuppressive toxicity, illustrating the profound challenge of finding a partner drug that can provide a pro-apoptotic signal without creating an intolerable safety profile.[16]

Analysis of Development Discontinuation and Regulatory Status

LCL-161 remains an investigational agent and has not received marketing authorization from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other major global regulatory authority.[47] Its development was largely discontinued at the Phase 2 stage.[18] The official reason cited by the originator, Novartis, for terminating key trials was a "change in development strategy".[17] This decision was likely a culmination of several factors:

1. Lack of Broad Monotherapy Efficacy: The failure to show objective responses in the initial Phase 1 solid tumor trial limited its potential as a standalone agent.
2. Challenging Safety Profile: The on-target risk of CRS necessitated careful management and limited the achievable dose intensity.
3. Combination Hurdles: The difficulty in identifying safe and effective combination partners, as evidenced by the topotecan trial, presented a significant obstacle to its primary path of development.
4. Niche Indication: While promising in myelofibrosis, this represents a relatively small market, which may not have justified the extensive resources required to navigate the drug's complexities for a single indication.

Collectively, the risk-reward profile and projected commercial potential were likely deemed insufficient to warrant continued investment, leading to the cessation of the program.

Future Outlook for LCL-161 and IAP Antagonists

Although the broad development of LCL-161 has been halted, the knowledge gained from its investigation provides valuable lessons for the entire SMAC mimetic class. The clear efficacy signal in myelofibrosis suggests that a potential, albeit niche, therapeutic role may still exist for IAP antagonists in diseases characterized by a high baseline inflammatory state.

The path forward for this drug class will depend on more sophisticated development strategies. Future clinical trials should incorporate biomarker-driven patient selection, prospectively identifying tumors with high cIAP1 expression (as in HPV[-] HNSCC) or an inflamed microenvironment. The most promising therapeutic avenue remains in combination, but partners must be chosen with a deep understanding of potential toxicity overlaps. Rather than combining with broadly myelosuppressive agents, future exploration should focus on combinations with agents that have non-overlapping toxicities, such as certain targeted therapies, epigenetic modulators, or specific immunotherapies where the complex immunomodulatory effects of SMAC mimetics can be carefully harnessed. The story of LCL-161 is not one of a failed mechanism, but of a potent mechanism that requires a precisely defined biological context and a carefully chosen therapeutic partner to be successful.

Works cited

1. LCL161 | CAS#1005342-46-0 | IAP inhibitor | MedKoo Biosciences, accessed November 2, 2025, https://www.medkoo.com/products/5578
2. Definition of SMAC mimetic LCL161 - NCI Drug Dictionary - National Cancer Institute, accessed November 2, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/smac-mimetic-lcl161
3. lcl161 - My Cancer Genome, accessed November 2, 2025, https://www.mycancergenome.org/content/drugs/LCL161/
4. LCL161 | IAP inhibitor | Mechanism | Concentration - Selleck Chemicals, accessed November 2, 2025, https://www.selleckchem.com/products/lcl161.html
5. LCL161 | IAP Inhibitor - MedchemExpress.com, accessed November 2, 2025, https://www.medchemexpress.com/LCL161.html
6. An Updated Review of Smac Mimetics, LCL161, Birinapant, and GDC-0152 in Cancer Treatment - MDPI, accessed November 2, 2025, https://www.mdpi.com/2076-3417/11/1/335
7. Initial Testing (Stage 1) of LCL161, a SMAC Mimetic, by the Pediatric Preclinical Testing Program - PMC - NIH, accessed November 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3253328/
8. The SMAC mimetic LCL-161 displays antitumor activity in preclinical ..., accessed November 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6290104/
9. LCL161, a SMAC mimetic, Preferentially Radiosensitizes Human Papillomavirus Negative Head and Neck Squamous Cell Carcinoma - PMC - NIH, accessed November 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6548673/
10. Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells... | Oncotarget, accessed November 2, 2025, https://www.oncotarget.com/article/12055/text/
11. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors - PubMed, accessed November 2, 2025, https://pubmed.ncbi.nlm.nih.gov/25113756/
12. Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors - ASCO Publications, accessed November 2, 2025, https://ascopubs.org/doi/abs/10.1200/JCO.2013.52.3993
13. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis | Request PDF - ResearchGate, accessed November 2, 2025, https://www.researchgate.net/publication/354037430_Final_results_of_a_phase_2_clinical_trial_of_LCL161_an_oral_SMAC_mimetic_for_patients_with_myelofibrosis
14. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis | Blood Advances - ASH Publications, accessed November 2, 2025, https://ashpublications.org/bloodadvances/article/5/16/3163/476582/Final-results-of-a-phase-2-clinical-trial-of
15. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis - PMC - PubMed Central, accessed November 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8405193/
16. A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies - Oxford Academic, accessed November 2, 2025, https://academic.oup.com/oncolo/article/28/7/640/7147832
17. Novartis Generic Drug Name LCL161 Trial Indication(s) Advanced solid tumors - novctrd.com, accessed November 2, 2025, https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14605
18. LCL-161 - Drug Targets, Indications, Patents - Synapse, accessed November 2, 2025, https://synapse.patsnap.com/drug/fa7ce5c4e54a4d3fbbfc160c775bdbb7
19. LCL-161 - precisionFDA, accessed November 2, 2025, https://precision.fda.gov/ginas/app/ui/substances/fca3197c-bcf5-485e-9613-d0ed20ba8395
20. Lcl-161 | C26H33FN4O3S | CID 24737642 - PubChem - NIH, accessed November 2, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Lcl-161
21. LCL-161 (NVP-LCL161, CAS Number: 1005342-46-0) | Cayman Chemical, accessed November 2, 2025, https://www.caymanchem.com/product/22420/lcl-161
22. LCL161 | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed November 2, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7912
23. LCL161 | IAP Inhibitor - Ambeed.com, accessed November 2, 2025, https://www.ambeed.com/products/lcl161.html
24. LCL 161 - AdisInsight - Springer, accessed November 2, 2025, https://adisinsight.springer.com/drugs/800031959
25. LCL161 (CAS 1005342-46-0) - Abcam, accessed November 2, 2025, https://www.abcam.com/en-us/products/biochemicals/lcl161-ab273616
26. Chemie Tek LCL-161, 10MG, 1005342-46-0 - Fisher Scientific, accessed November 2, 2025, https://www.fishersci.com/shop/products/lcl161-10mg/NC0605628
27. LCL-161 82073 - BPS Bioscience, accessed November 2, 2025, https://bpsbioscience.com/lcl-161-82073
28. LCL-161: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed November 2, 2025, https://go.drugbank.com/drugs/DB12085
29. Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice, accessed November 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6744692/
30. The SMAC mimetic LCL161 is a direct ABCB1/MDR1-ATPase activity modulator and BIRC5/Survivin expression down-regulator in cancer cells - PubMed, accessed November 2, 2025, https://pubmed.ncbi.nlm.nih.gov/32497533/
31. LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling - Frontiers, accessed November 2, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1179827/full
32. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC - PMC - PubMed Central, accessed November 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5062899/
33. An Updated Review of Smac Mimetics, LCL161, Birinapant, and GDC-0152 in Cancer Treatment - ResearchGate, accessed November 2, 2025, https://www.researchgate.net/publication/348142207_An_Updated_Review_of_Smac_Mimetics_LCL161_Birinapant_and_GDC-0152_in_Cancer_Treatment
34. SMAC mimetics induce human macrophages to phagocytose live cancer cells | Immunotherapy Advances | Oxford Academic, accessed November 2, 2025, https://academic.oup.com/immunotherapyadv/article/5/1/ltaf026/8193980
35. Birinapant, a Smac-Mimetic with Improved Tolerability for the Treatment of Solid Tumors and Hematological Malignancies | Journal of Medicinal Chemistry - ACS Publications, accessed November 2, 2025, https://pubs.acs.org/doi/10.1021/jm500176w
36. LCL161 - IAP Antagonist for Apoptosis Modulation - APExBIO, accessed November 2, 2025, https://www.apexbt.com/lcl161.html
37. The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma | Blood Advances | American Society of Hematology, accessed November 2, 2025, https://ashpublications.org/bloodadvances/article/2/23/3516/16140/The-SMAC-mimetic-LCL-161-displays-antitumor
38. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus–negative Head and Neck Squamous Cell Carcinoma - AACR Journals, accessed November 2, 2025, https://aacrjournals.org/mct/article/18/6/1025/92716/LCL161-a-SMAC-mimetic-Preferentially
39. Study Details | NCT01098838 | Safety and Efficacy of LCL161 in ..., accessed November 2, 2025, https://www.clinicaltrials.gov/study/NCT01098838
40. Study Details | NCT02098161 | LCL161 in Treating Patients With ..., accessed November 2, 2025, https://www.clinicaltrials.gov/study/NCT02098161
41. Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis - ASH Publications, accessed November 2, 2025, https://ashpublications.org/blood/article/134/Supplement_1/555/426590/Final-Results-of-Phase-2-Clinical-Trial-of-LCL161
42. Multiple Myeloma Completed Phase 2 Trials for LCL-161 (DB12085) | DrugBank Online, accessed November 2, 2025, https://go.drugbank.com/indications/DBCOND0028259/clinical_trials/DB12085?phase=2&status=completed
43. SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma - Mayo Clinic, accessed November 2, 2025, https://www.mayo.edu/research/clinical-trials/cls-20112341
44. Study Details | NCT01955434 | SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma | ClinicalTrials.gov, accessed November 2, 2025, https://clinicaltrials.gov/study/NCT01955434?term=smac&viewType=Table&rank=1
45. LCL-161 Completed Phase 1 Trials for Multiple Myeloma (MM) Treatment | DrugBank Online, accessed November 2, 2025, https://go.drugbank.com/drugs/DB12085/clinical_trials?conditions=DBCOND0040908&phase=1&purpose=treatment&status=completed
46. Future Therapeutic Directions for Smac-Mimetics - PMC - NIH, accessed November 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7072318/
47. LCL-161 | MedPath, accessed November 2, 2025, https://trial.medpath.com/drug/f875ff4e734e2869/lcl-161
48. LCL-161 Completed Phase 1 Trials for Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma Treatment - DrugBank, accessed November 2, 2025, https://go.drugbank.com/drugs/DB12085/clinical_trials?conditions=DBCOND0110710&phase=1&purpose=treatment&status=completed
49. Solid Tumours Completed Phase 1 Trials for LCL-161 (DB12085) | DrugBank Online, accessed November 2, 2025, https://go.drugbank.com/indications/DBCOND0037606/clinical_trials/DB12085?phase=1&status=completed
50. Study Details | NCT02649673 | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies | ClinicalTrials.gov, accessed November 2, 2025, https://www.clinicaltrials.gov/study/NCT02649673
51. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis | Blood Advances - ASH Publications, accessed November 2, 2025, https://ashpublications.org/bloodadvances/article-abstract/5/16/3163/476582
52. Research Progress in the Use of Small Molecule Smac Mimetics in Combination Therapy of Cancer - PubMed, accessed November 2, 2025, https://pubmed.ncbi.nlm.nih.gov/38766833/
53. European Medicines Agency (EMA), accessed November 2, 2025, https://www.ema.europa.eu/en/medicines